The take home message
A molecular glue degrader is a new type of cancer drug that tricks cancer cells into dismantling an important protein they need to survive.
Instead of just slowing down the cancer cell, the goal is to make the cell throw away one of its most important parts.
Cells already have a garbage disposal system
Every cell has its own cleanup and recycling system.
Cells are always:
· checking their proteins
· finding damaged or unneeded proteins
· breaking down unwanted proteins by chopping them up
These are normal housekeeping functions that keep cells healthy.
In ALK-positive cancer, an abnormal ALK fusion protein causes cancer cells to survive and multiply. A molecular glue degrader can help the cell discard this abnormal ALK protein.
The “garbage tag” system
A molecular glue drug works by “sticking” two things together that normally would not connect.
One is the ALK cancer protein. The other is the cell’s garbage-tagging machinery.
The molecular glue drug seeks out the mutated ALK protein and helps attach a “trash tag” to the protein. Once tagged, the cell’s recycling system recognizes it as garbage and destroys it.
How molecular glues are different from ALK TKIs
Traditional ALK drugs like Alectinib or Lorlatinib work by blocking the activity of the ALK protein.
This blockade can stop cancer cells from growing, and many cancer cells die. But over time, some cells can change and become resistant to the drug.
A molecular glue degrader works differently. Instead of only blocking the ALK protein, it tries to remove the protein completely.
Researchers hope this may lead to deeper or longer-lasting responses for some patients.
Current limitations
This area of research is exciting, but it is still early.
Finding a molecular glue drug that works well is difficult. Scientists may need to test thousands of compounds to find one that safely targets the right protein.
Researchers also must make sure the drug mainly affects cancer cells and does not damage too many healthy cells.
Like other cancer drugs, resistance can still happen. Cancer cells may develop new changes that undermine either the tagging system or the protein removal machinery.
A molecular glue trial for ALK-positive patient
A new molecular glue drug is now being tested for ALK-positive lung cancer. It is an experimental drug designed to destroy the ALK protein instead of simply blocking it.
The drug is called TRIANA-116. It is an early clinical trial, so researchers are still learning:
· what dose works best
· what side effects patients may have
· whether the drug helps shrink tumors
Researchers are especially keen to discover whether this drug can help patients whose cancer stopped responding to earlier ALK drugs like Lorlatinib.
Who may be able to join?
The rules are different for different parts of the study, but the trial is mainly for adults with advanced ALK-positive lung cancer.
Groups in the trial include patients who:
· already took Lorlatinib
· already took several ALK drugs
· had cancer that continued growing after treatment
One group may also include patients who have not yet taken an ALK drug.
Where is the trial open?
As of May 2026, the trial is recruiting patients at several cancer centers in the United States, including:
· University of Colorado Cancer Center — Aurora, Colorado
· Washington University Medical Center — St. Louis, Missouri
· Memorial Sloan Kettering Cancer Center — New York City, New York
· Taylor Cancer Research Center — Maumee, Ohio
· SCRI Oncology Partners — Nashville, Tennessee
· START Mountain Region — West Valley City, Utah
· NEXT Virginia — Fairfax, Virginia
Stay tuned, as more locations may open later.
Patients interested in the study can search online for: “TRIANA-116 trial” or “NCT07491497”
They can also ask their oncologist whether this trial may be a good fit for them.
It is still very early, and nobody yet knows whether molecular glue drugs will work better than today’s ALK drugs. But researchers are excited because this is a completely new way of attacking ALK-positive cancer.
Clinical Trials Currently Recruiting for ALK-positive Cancers
General Information About Clinical Trials
Author: Ellee Urban
